Cellectis (CLLS) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free CLLS Stock Alerts $2.57 -0.10 (-3.75%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 4:52 AM | americanbankingnews.comCellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.comJune 6, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on Cellectis in a research report on Thursday. They set a "sell" rating on the stock.June 4, 2024 | globenewswire.comCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaJune 1, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) Given Market Outperform Rating at JMP SecuritiesMay 31, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Rating Reiterated by JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $6.00 price target on shares of Cellectis in a report on Friday.May 29, 2024 | finance.yahoo.comCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024May 29, 2024 | globenewswire.comCellectis' Annual Shareholders General Meeting to be Held on June 28, 2024May 29, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Passes Below 50-Day Moving Average of $2.75Cellectis (NASDAQ:CLLS) Share Price Passes Below 50 Day Moving Average of $2.75May 28, 2024 | investorplace.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024May 27, 2024 | globenewswire.comCellectis to Report First Quarter 2024 Financial Results on May 28, 2024May 6, 2024 | globenewswire.comCellectis Announces Completion of the Additional Equity Investment by AstraZenecaMay 2, 2024 | globenewswire.comCellectis Appoints Arthur Stril as Interim Chief Financial OfficerMay 1, 2024 | benzinga.comCellectis Stock (NASDAQ:CLLS), Earnings Estimates, EPS, and RevenueApril 29, 2024 | globenewswire.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023April 24, 2024 | seekingalpha.comCLLS Cellectis S.A.April 22, 2024 | globenewswire.comCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsApril 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingApril 10, 2024 | finance.yahoo.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 10, 2024 | globenewswire.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 8, 2024 | globenewswire.comCellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingApril 1, 2024 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Sees Significant Decrease in Short InterestCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 679,300 shares, a decline of 6.6% from the February 29th total of 727,500 shares. Based on an average daily trading volume, of 50,500 shares, the days-to-cover ratio is presently 13.5 days.March 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday TradingMarch 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday TradingFebruary 27, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Crosses Below 50 Day Moving Average of $2.99Cellectis (NASDAQ:CLLS) Shares Pass Below 50 Day Moving Average of $2.99February 24, 2024 | finance.yahoo.comCellectis S.A. (CLLS)February 20, 2024 | wsj.comCellectis S.A. ADRFebruary 18, 2024 | marketbeat.comBaillie Gifford & Co. Has $1.84 Million Stock Holdings in Cellectis S.A. (NASDAQ:CLLS)Baillie Gifford & Co. decreased its position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) by 18.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,164,009 shares of the biotFebruary 3, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Stock Price Passes Above Fifty Day Moving Average of $3.02Cellectis (NASDAQ:CLLS) Stock Passes Above 50 Day Moving Average of $3.02February 3, 2024 | finance.yahoo.comMonthly information on share capital and company voting rightsJanuary 26, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%January 16, 2024 | msn.comCellectis draws down second tranche under EIB credit facilityJanuary 16, 2024 | finance.yahoo.comCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)December 31, 2023 | marketbeat.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Decreases By 19.9%Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 840,900 shares, a decline of 19.9% from the November 30th total of 1,050,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the days-to-cover ratio is presently 0.5 days.December 22, 2023 | finance.yahoo.comCellectis Reports Results from Shareholders Meeting Held on December 22, 2023December 16, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 20.85% to 11.75December 15, 2023 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Short Interest UpdateCellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,050,000 shares, a drop of 28.1% from the November 15th total of 1,460,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the days-to-cover ratio is currently 0.6 days.November 17, 2023 | finance.yahoo.comCellectis’ Shareholders Meeting to be Held on December 22, 2023November 15, 2023 | finance.yahoo.comCellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNovember 12, 2023 | morningstar.comCellectis SA ADR CLLSNovember 8, 2023 | finance.yahoo.comCellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)November 6, 2023 | seekingalpha.comCellectis Non-GAAP EPS of -$0.58, revenue of $1.88MNovember 3, 2023 | benzinga.comEarnings Preview: CellectisNovember 2, 2023 | finance.yahoo.comCellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNovember 1, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 11.03% to 11.29November 1, 2023 | finance.yahoo.comCellectis to Report Third Quarter 2023 Financial Results on November 6, 2023November 1, 2023 | markets.businessinsider.comCellectis Announces Collaboration Agreement With AstraZeneca; To Receive Up To $245 MlnNovember 1, 2023 | theglobeandmail.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNovember 1, 2023 | msn.comWhy Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?November 1, 2023 | msn.comAstraZeneca to invest $245m in French biotech company Cellectis Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Hurry! Buy this stock before the Robinhood traders do! (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades CLLS Media Mentions By Week CLLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.000.76▲Average Medical News Sentiment CLLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼31▲CLLS Articles Average Week Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LXEO News KYTX News ADPT News CABA News EDIT News VYGR News OCGN News ALEC News TCRX News FATE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored